Ionis Pharmaceuticals clinical trials we track

Check company identity source

Phase 3 20 trials

TrialDrugs studiedStatusPrimary completion
A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric ParticipantsNCT07727538OlezarsenRecruiting2030-08Estimated
Donidalorsen Treatment in Children With Hereditary AngioedemaNCT07298447DonidalorsenRecruiting2029-06Estimated
CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)NCT07782827obudanersenRecruiting2028-05Estimated
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)NCT05667493EplontersenEnrolling by invitation2029-08Estimated
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid PolyneuropathyNCT05071300EplontersenActive not recruiting2029-08Estimated
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)NCT05130450OlezarsenActive not recruiting2028-02Estimated
REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman SyndromeNCT06914609obudanersenActive not recruiting2027-08Estimated
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With VolanesorsenNCT05185843OlezarsenActive not recruiting2027-06Estimated
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)NCT05681351OlezarsenActive not recruiting2027-03Estimated
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)NCT05392114DonidalorsenActive not recruiting2026-12Estimated
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)NCT04768972ION363Active not recruiting2026-06-17Actual
A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)NCT04849741zilganersenActive not recruiting2025-08-22Actual
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)NCT04136171EplontersenCompleted2026-03-25Actual
A Study of Olezarsen Administered Subcutaneously to Participants With Severe HypertriglyceridemiaNCT05552326OlezarsenCompleted2024-12-17Actual
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe HypertriglyceridemiaNCT05079919OlezarsenCompleted2024-10-22Actual
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe HypertriglyceridemiaNCT05610280OlezarsenCompleted2024-08-08Actual
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)NCT05139810DonidalorsenCompleted2023-11-09Actual
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)NCT04568434OlezarsenCompleted2023-07-14Actual
NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid PolyneuropathyNCT04136184Eplontersen, InotersenCompleted2023-04-11Actual
Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)NCT02175004InotersenCompleted2020-09-11Actual

Phase 2 12 trials

TrialDrugs studiedStatusPrimary completion
A Study to Assess the Safety, Tolerability and Efficacy of ION775NCT07604974ION775Recruiting2027-09Estimated
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia VeraNCT05143957sapablursenCompleted2025-06-26Actual
An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary AngioedemaNCT04307381DonidalorsenCompleted2025-01-24Actual
GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)NCT03815825IONIS-FB-LRxCompleted2024-04-18Actual
A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA NephropathyNCT04014335IONIS-FB-LRxCompleted2024-02-08Actual
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224NCT04932512ION224Completed2024-01-10Actual
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe HypertriglyceridemiaNCT05355402OlezarsenCompleted2023-03-22Actual
A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled HypertensionNCT05314439ION904Completed2023-01-31Actual
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection FractionNCT04836182IONIS-AGT-LRxCompleted2022-10-19Actual
A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With AcromegalyNCT04522180GHR-LRXCompleted2022-07-15Actual
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood PressureNCT04714320IONIS-AGT-LRxCompleted2022-06-29Actual
Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)NCT04059406sapablursenTerminated2023-03-28Actual

Phase 1 / 2 3 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 158 participants (planned). After: 156 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 3 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Apr 2026. After: 25 Mar 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change From Baseline at Month 6 (average of Weeks 25 and 27) in Fasting Triglycerides (TG). After: Measure: Percent Change From Baseline in Fasting TG at Month 6.

Primary completion date changed

Before: 22 Mar 2023. After: 17 Jan 2023.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity. After: Measure: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Measure: Percentage of Participants With Clinically Meaningful Changes in Clinical Laboratory Assessments Measure: Percentage of Participants With Clinically Meaningful Changes in Vital Signs Measure: Percentage of Participants With Clinically Meaningful Changes in Electrocardiograms (ECGs) Parameters Measure: Percentage of Participants Who Received At Least One Concomitant Medication.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) in Cohort 1. After: Measure: Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) Without Caregiver Input in Cohort 1.

Planned enrollment decreased by 52 participants

Before: 210 participants (planned). After: 158 participants (planned).

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 800 participants (planned). After: 885 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source